Regulation of Prothrombinase Activity by Protein S

Summary

The independent effect of protein S as prothrombinase inhibitor has been proposed to depend on binding to both coagulation factors Va and factor Xa or on the binding to phospholipid thereby limiting the phospholipid available for prothrombinase activity. In this study we show that plasma concentrations of protein S (300 nM) equilibrated with the prothrombinase components (factor Va, factor Xa, phospholipid) cause a profound inhibition at low phospholipid concentrations (~0.2 μM). This inhibition by protein S of prothrombinase activity is abrogated with increasing phospholipid concentrations. Modeling of the effect of protein S on prothrombinase based only on the reported affinity of protein S for phospholipids (K_d ~ 10^-8 M) in an equilibrium model (Clotspeed), predicted the experimentally obtained thrombin generation rates at low phospholipid in the presence of protein S based on the diminished available phospholipid binding sites for the prothrombinase components. Consistently, initial rates of prothrombinase activity are already maximally inhibited when protein S is preincubated with the phospholipid prior to the addition of factor Xa, factor Va and pro-thrombin. The results indicate that the order of addition of prothrombinase components and the availability of phospholipid may have a profound influence on observed effects of protein S on prothrombinase activity. All prothrombinase components (factor Xa, factor Va, phospholipid) become available during the course of the physiological thrombin generation. The effect of protein S was therefore studied on tissue factor-induced, platelet-dependent thrombin generation. Protein S delayed and inhibited the rate of thrombin generation of tissue factor-induced thrombin formation when surface is provided at physiologic concentrations using isolated platelets (2 × 10⁸/ml). In contrast, protein S hardly affected thrombin generation in this model when platelets were pre-activated with collagen. Furthermore, the observed effects of addition of protein C and thrombomodulin in the absence or presence of protein S on tissue factor-induced, platelet-dependent thrombin generation, indicate that protein S and protein C may cooperate in the regulation of prothrombinase activity through independent mechanisms.

• References

• 1 Dahlbäck B. Protein S and C4b-binding protein: components involved in the regulation of the protein C anticoagulant system. Thromb Haemost 1991; 66: 49-61.
• 2 Hessing M. The interaction between complement component C4b-binding protein and the vitamin K-dependent protein S forms a link between blood coagulation and the complement system. Biochem J 1991; 277: 581-92.
• 3 DiScipio RG, Davie EW. Characterization of protein S, a gamma-carboxyglutamic acid containing protein from bovine and human plasma. Biochemistry 1979; 18: 899-904.
• 4 Suttie JW. Vitamin K-dependent carboxylase. Annu Rev Biochem 1985; 54: 459-77.
• 5 Kalafatis M, Egan JO, van 't Veer C, Mann KG. Regulation and regulatory role of gamma-carboxyglutamic acid containing clotting factors. Crit Rev in Eukar Gene Expr 1996; 6: 87-101.
• 6 Osterud B, Rapaport I S. Activation of factor IX by the reaction product of tissue factor and factor VII. Proc Natl Acad Sci 1977; 74: 5260-4.
• 7 Davie EW, Fujikawa K, Kisiel W. The coagulation cascade: initiation, maintenance, and regulation. Biochemistry 1991; 30: 10363-70.
• 8 Mann KG, Krishnaswamy S, Lawson JH. Surface-dependent hemostasis. Hemostasis, Sem in Hematology 1992; 29: 213-27.
• 9 Broze Jr GJ. Tissue factor pathway inhibitor. Thromb Haemost 1995; 74: 90-936.
• 10 Olson ST, Björk I. Regulation of thrombin activity by antithrombin and heparin. Seminars Thromb Hemost 1994; 20: 373-409.
• 11 Esmon CT. Thrombomodulin as a model of molecular mechanisms that modulate protease specificity and function at the vessel wall surface. FASEB J 1995; 9: 946-55.
• 12 Comp PC, Esmon CT. Recurrent venous thrombosis in patients with a partial deficiency of protein S. N Engl J Med 1984; 311: 1525-8.
• 13 Walker FJ. Regulation of activated protein C by a new protein. A possible function for bovine protein S. J Biol Chem 1980; 255: 5521-4.
• 14 Walker FJ. Regulation of activated protein C by protein S. The role of phospholipid in factor Va inactivation. J Biol Chem 1981; 256: 11128-31.
• 15 Fulchner CA, Gardiner JE, Griffin JH, Zimmerman TS. Proteolytic inactivation of human factor VIII procoagulant protein by activated protein C and its analogy with factor V. Blood 1984; 63: 486-9.
• 16 Koedam JA, Meijers JCM, Sixma JJ, Bouma BN. Inactivation of human factor VIII by activated protein C. J Clin Invest 1988; 82: 1236-43.
• 17 Solymoss S, Tucker MM, Tracy PB. Kinetics of inactivation of membrane-bound factor Va by activated protein C. J Biol Chem 1988; 263: 14884-90.
• 18 Heeb MJ, Mesters RM, Tans G, Rosing J, Griffin JH. Binding of protein S to factor Va associated with inhibition of prothrombinase that is independent of activated protein C. J Biol Chem 1993; 268: 2872-7.
• 19 Hackeng TM, van 't Veer C, Meijers JCM, Bouma BN. Human protein S inhibits prothrombinase complex activity on endothelial cells and platelets via direct interactions with factor Va and Xa. J Biol Chem 1994; 269: 21051-8.
• 20 van 't Veer C, Hackeng TM, Biesbroeck D, Sixma JJ, Bouma BN. Increased prothrombin activation in protein S-deficient plasma under flow conditions on endothelial cell matrix: an independent function of protein S in plasma. Blood 1995; 85: 1815-21.
• 21 Koppelman SJ, Hackeng TM, Sixma JJ, Bouma BN. Inhibition of the intrinsic factor X activating complex by protein S: evidence for a specific binding of protein S to factor VIII. Blood 1995; 86: 1062-71.
• 22 Heeb MJ, Rosing J, Bakker HM, Fernandez JA, Tans G, Griffin JH. Protein S binds to and inhibits factor Xa. Proc Natl Acad Sci USA 1994; 91: 2728-32.
• 23 van Wijnen M, Stam JG, van 't Veer C, Meijers JCM, Reitsma PH, Bertina RM, Bouma BN. The interaction of protein S with the phospholipid surface is essential for the activated protein C-independent activity of protein S. Thromb Haemost 1996; 76: 397-403.
• 24 van 't Veer C, Kalafatis M, Bertina RM, Simioni P, Mann KG. Increased prothrombin activation as a result of the Arg⁵⁰⁶ Gln mutation in factor V LEIDEN. J Biol Chem 1997; 272: 20721-9.
• 25 Bajaj SP, Rapaport I S, Prodanos C. A simplified procedure for purification of human prothrombin, factor IX and factor X. Prep Biochem 1981; 11: 397-412.
• 26 van 't Veer C, Mann KG. Regulation of tissue factor initiated thrombin generation by the stoichiometric inhibitors tissue factor pathway inhibitor, antithrombin-III and heparin cofactor-II. J Biol Chem 1997; 272: 4367-79.
• 27 Dahlbäck B. Purification of human vitamin K-dependent protein S and its limited proteolysis by thrombin. Biochem J 1983; 209: 837-46.
• 28 van 't Veer C, Golden NJ, Kalafatis M, Mann KG. Inhibitory mechanism of the protein C pathway on tissue factor-induced thrombin generation. Synergystic effect in combination with tissue factor pathway inhibitor. J Biol Chem 1997; 272: 7983-94.
• 29 Lu D, Xie RL, Rydzewski A, Long GL. The effect of N-linked glycosylation on molecular weight, thrombin cleavage and functional activity of human protein S. Thromb Haemost 1997; 77: 1156-63.
• 30 Nesheim M E, Katzmann JA, Tracy PB, Mann KG. Factor V. Meth Enzymol 1981; 80: 249-74.
• 31 Kane W, Majerus PW. Purification and characterization of human coagulation factor V. J Biol Chem 1981; 256: 1002-7.
• 32 Griffith MJ, Noyes CM, Church FC. Reactive site peptide structural similarity between heparin cofactor II and antithrombin III. J Biol Chem 1985; 260: 2218-25.
• 33 Barenholz Y, Gibbs D, Litman BJ, Goll J, Thompson TE, Carlson FD. A simple method for the preparation of homogeneous phospholipid vesicles. Biochemistry 1977; 16: 2806-10.
• 34 Bloom JW, Nesheim ME, Mann KG. Phospholipid-binding properties of bovine factor V and factor Va. Biochemistry 1979; 18: 4419-25.
• 35 Leong L, Henrikse RA, Kermode JC, Rittenhouse SE, Tracy PB. The thrombin high-affinity binding site on platelets is a negative regulator of thrombin induced platelet activation. Structure-function studies using two mutant thrombins, Quick I and Quick II. Biochemistry 1992; 31: 2567-76.
• 36 Nesheim ME, Tracy RP, Mann KG. ìClotspeedî, a mathematical simulation of the functional properties of prothrombinase. J Biol Chem 1984; 259: 1447-53.
• 37 Krishnaswamy S. Prothrombin complex assembly. Contributions of protein-protein and protein-membrane interactions toward complex formation. J Biol Chem 1990; 265: 3708-18.
• 38 Lim TK, Bloomfield VA, Nelsestuen GL. Structure of the prothrombin- and blood clotting factor X-membrane complexes. Biochemistry 1977; 16: 4177-81.
• 39 Higgins DL, Mann KG. The interaction of bovine factor V and factor V-derived peptides with phospholipid vesicles. J Biol Chem 1983; 258: 6503-8.
• 40 Zwaal RFA, Schroit AJ. Pathophysiologic implications of membrane phospholipid assymetry in blood cells. Blood 1997; 89: 1121-32.
• 41 Jenny RJ, Pitmann DD, Toole JJ, Kriz RW, Aldape RA, Hewick RM, Kaufmann RJ, Mann KG. Complete cDNA and derived amino acid sequence of human factor V. Proc Natl Acad Sci USA 1987; 84: 4846-50.
• 42 Schwalbe R, Dahlbäck B, Hillarp A, Nelsestuen G. Assembly of protein S and C4b-binding protein on membranes. J. Biol. Chem 1990; 265: 16074-81.
• 43 Pieters J, Lindhout T, Hemker HC. In situ-generated thrombin is the only enzyme that effectively activates factor VIII and factor V in thromboplastin-activated plasma. Blood 1989; 74: 1021-4.
• 44 Butenas S, van 't Veer C, Mann KG. Evaluation of the initiation phase of blood coagulation using ultrasensitive assays for serine proteases. J Biol Chem 1997; 272: 1527-33.
• 45 Marciniack E. Factor Xa inactivation by antithrombin III. Evidence for biological stabilization of factor Xa by factor V-phospholipid complex. Br J Haematol 1973; 24: 391-400.
• 46 Mast AE, Broze Jr GJ. Physiological concentrations of tissue factor pathway inhibitor do not inhibit prothrombinase. Blood 1996; 87: 1845-50.
• 47 Tracy PB, Eide LL, Mann KG. Human prothrombinase complex assembly and function on isolated peripheral blood cell populations. J Biol Chem 1985; 260: 2119-24.
• 48 Krishnaswamy S, Jones KC, Mann KG. Prothrombinase complex assembly. Kinetic mechanism of enzyme assembly on phospholipid vesicles. J Biol Chem 1988; 263: 3823-34.
• 49 Reutelingsperger CPM, Hornstra G, Hemker HC. Isolation and partial purification of a novel anticoagulant from arteries of human umbilical cord. Eur J Biochem 1985; 151: 625-9.
• 50 Andree HAM, Stuart MCA, Hermens WT, Reutelingsperger CPM, Hemker HC, Frederik PM, Willems GM. Clustering of lipid-bound Annexin V may explain its anticoagulant effect. J Biol Chem 1992; 267: 17907-12.
• 51 van Heerde WL, Poort S, van 't Veer C, Reutelingsperger CPM, de Groot PG. Binding of recombinant annexin V to endothelial cells: effect of annexin V binding on endothelial-cell-mediated thrombin formation. Biochemical J 1994; 302: 305-12.
• 52 London F, Ahmad SS, Walsh PN. Annexin V inhibition of factor IXa-catalyzed factor X activation on human platelets and on negatively-charged phospholipid vesicles. Biochemistry 1996; 35: 16886-97.
• 53 Bouchard BA, Catcher CS, Thrash BR, Adida C, Tracy PB. Effector cell protease receptor-1, a platelet activation-dependent membrane protein, regulates prothrombinase-catalyzed thrombin generation. J Biol Chem 1997; 272: 9244-51.
• 54 van Wijnen M, van 't Veer C, Meijers JCM, Bertina RM, Bouma BN. A plasma coagulation assay for an activated protein C-independent anticoagulant activity of protein S. Thromb Haemost 1998; 80: 930-5.